Skip to content

PR-Web

Press releases worldwide

  • Home
  • Contact
  • Datenschutzerklärung
  • Legal notice

Author: Firma EvidentIQ Group

Clindex by EvidentIQ Group Launches Revolutionary Site Feasibility Feature to Transform Clinical Trial Management

Posted on 23. June 202524. June 2025 by Firma EvidentIQ Group Posted in General Tagged Centralized, clinical, compliance, data, eclinical, evaluation, Feasibility, innovation, management, process, security, site, Sponsors, trial, Workflows

EvidentIQ Group GmbH announced today the launch of an innovative Site Feasibility feature within Clindex, one of its Electronic Data Capture (EDC) systems. This transformative addition to the Clindex eClinical platform introduces a comprehensive solution to streamline clinical trial site […]

Read More

EvidentIQ Germany GmbH confirmed as a Platinum Pharma Supplier

Posted on 12. August 2024 by Firma EvidentIQ Group Posted in General Tagged certification, clients, company, compliance, evidentiq, global, healthcare, network, pharma, pharmaceutical, platinum, program, services, trusted, with

EvidentIQ Germany was recognized as a Platinum Pharma Supplier by Qualifyze’s quality compliance program. This prestigious distinction acknowledges EvidentIQ Germany’s commitment to providing high-quality products and reliable services to the healthcare and pharmaceutical industries. Receiving the Platinum Quality Compliance Certificate […]

Read More

10 Years of Successful Partnership between EvidentIQ Germany and Cardialysis in the Field of Clinical Studies

Posted on 8. January 202412. January 2024 by Firma EvidentIQ Group Posted in General Tagged cardiac, cardialysis, clinical, coronary, CRO, data capture, ecg, edc, evidentiq, mri, patients, pmda, research, ultrasound, xclinical

EvidentIQ Germany, formerly known as XClinical, a top provider of EDC software, is proud to mark a decade of fruitful collaboration with Cardialysis, a renowned CRO & Core Laboratory based in the Netherlands. For the past ten years, EvidentIQ Germany […]

Read More

EvidentIQ is pleased to announce the addition of Asthenis GmbH to their comprehensive eClinical solutions group.

Posted on 5. October 202312. January 2024 by Firma EvidentIQ Group Posted in General Tagged acquisition, asthenis, clinical, eclinical, edc, evidentiq, medical, new offer, oncology, reatment

Today, EvidentIQ, a leading provider of end-to-end eClinical and Patient Insights solutions, announced the acquisition of Asthenis GmbH, the market leader in cancer documentation software in the DACH region (Germany, Austria and Switzerland).  EvidentIQ, based in Hamburg, is a leading […]

Read More

EvidentIQ Announces Change of Leadership

Posted on 5. September 202312. January 2024 by Firma EvidentIQ Group Posted in General Tagged align, clinical, company, eclinical, evidentiq, healthcare, management, market, new, restructuring, solutions

Today, EvidentIQ, a leading provider of end-to-end eClinical and Patient Insights solutions, proudly announces a strategic leadership restructuring, setting the stage for the company’s continued growth and commitment to delivering unparalleled results for its clients. After three highly successful years […]

Read More

Quinta Analytica Partners with EvidentIQ to Enhance Efficiency of Phase 1 Studies

Posted on 22. June 202312. January 2024 by Firma EvidentIQ Group Posted in General Tagged analytica, clindex, clinical, ctms, data collection, data entry, eclinical, edc, evidentiq, phase 1, quinta, solutions

EvidentIQ, the innovative provider of advanced clinical trial management solutions has joined forces with Quinta Analytica, a renowned GCP/GLP/GMP-certified European CRO and part of the Conscio Group. This collaboration aims to enhance the efficiency and effectiveness of data collection processes […]

Read More

Carenity, part of the EvidentIQ Group, announces change in leadership

Posted on 1. June 202312. January 2024 by Firma EvidentIQ Group Posted in General Tagged Carenity, change management, company, evidentiq, future, health, industry, lise radoszycki, michael chekroun, new president, rwe

Michael Chekroun, founder of Carenity and outgoing President, will be stepping down from his role as of today. Lise Radoszycki, former COO, will be taking the helm as the new President, bringing extensive experience and expertise that will propel the […]

Read More

Managed Service Model for OpenStudyBuilder

Posted on 25. May 202312. January 2024 by Firma EvidentIQ Group Posted in General Tagged cdisc, clinical, data, evidentiq, mdr, neo4j, openstudybuilder

EvidentIQ launches a new Managed Service Model that not only supports the use of the open-source solution OpenStudyBuilder, but also helps clients customizing it to their specific requirements. Last year EvidentIQ  released alongside Novo Nordisk, Neo4j, and Microsoft, a new […]

Read More

E2B Mailer: Safety Notifications Made Easy

Posted on 5. May 202312. January 2024 by Firma EvidentIQ Group Posted in General Tagged adrs, drug, E2B, edc, evidentiq, patients, pv, research, software, study, transit, trial

EvidentIQ launches a new tool designed specifically to bridge the gap between a simple reporting and a PV system.   EvidentIQ aspired to create a tool that could solve the problem of having a reliable safety notification tool to monitor adverse […]

Read More

EvidentIQ and Keyrus Life Science are building a strategic partnership

Posted on 9. January 202312. January 2024 by Firma EvidentIQ Group Posted in General Tagged clinical, clinical trials, ctms, eCOA, eConsent, edc, evidentiq, keyrus, partnership, research, rwe

Today, EvidentIQ, a leading clinical data science group and Keyrus Life Science, the Connected Contract Research Organization (C²RO), announced the signing of their partnership. The synergy between both companies will improve automation, efficiency and agility in clinical research by leveraging […]

Read More

Posts navigation

Older posts

Copyright 2016. All rights reserved.


Back To Top
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.OkRead more